Identification of serum biomarkers for lung cancer using magnetic bead-based SELDI-TOF-MS

Acta Pharmacologica Sinica

Volumn 32, Issue 12, 2011, Pages 1537-1542

  Song, Qi Bin ^a   Hu, Wei Guo ^a   Wang, Peng ^b   Yao, Yi ^a   Zeng, Hua Zong ^c  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c TONGJI UNIVERSITY   (China)

Author keywords

human lung cancer; magnetic beads; SELDI TOF MS; serum biomarker

Indexed keywords

AMYLOID A PROTEIN; BIOLOGICAL MARKER; CHAPERONIN; HEMOGLOBIN BETA CHAIN; HEMOGLOBIN SUBUNIT BETA; PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CHILD; COMPUTER PROGRAM; CONTROLLED STUDY; DATA BASE; FEMALE; HUMAN; INFORMATION PROCESSING; LUNG CANCER; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MODEL; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

HUMANS; LUNG NEOPLASMS; MAGNETICS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 82955194970     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.137     Document Type: Article

References (21)

1. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004; 350: 379-92. (Pubitemid 38101633)
2. Herbst RS, Heymach JV, Lippman SM. Lung Cancer. N Engl J Med 2008; 359: 1367-80.
3. Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA. Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov 2002; 1: 683-95. (Pubitemid 47384843)
4. Singh N, Agarwal R, Aggarwal AN. Quality-of-life assessment in trials of lung cancer. Lancet 2007; 370: 933
5. Schneider J, Velcovsky HG, Morr H, Katz N, Neu K, Eigenbrodt E. Comparison of the tumor markers tumor M2-PK, CEA, CYFRA21-1, NSE and SCC in the diagnosis of lung cancer. Anticancer Res 2000; 20: 5053-8. (Pubitemid 32319079)
6. Ardizzoni A, Cafferata MA, Tiseo M, Filiberti R, Marroni P, Grossi F, et al. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Cancer 2006; 107: 2842-9. (Pubitemid 44937038)
7. Holdenrieder S, von Pawel J, Dankelmann E, Duell T, Faderl B, Markus A, et al. Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer. Lung Cancer 2009; 63: 128-35.
8. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359: 572-7. (Pubitemid 34178440)
9. Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004; 64: 5882-90. (Pubitemid 39095590)
10. Goncalves A, Bertucci F, Birnbaum D, Borg JP. Protein profiling SELDITOF and breast cancer: clinical potential applications. Med Sci (Paris) 2007; 23: 23-6. (Pubitemid 46456161)
11. Baumann S, Ceglarek U, Fiedler GM, Lembcke J, Leichtle A, Thiery J. Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry. Clin Chem 2005; 51: 973-80. (Pubitemid 40740877)
12. Trygg J, Holmes E, Lundstedt T. Chemometrics in metabonomics. J Proteome Res 2007; 6: 469-79. (Pubitemid 46340151)
13. Smith CA, Want EJ, O'Maille G, Abagyan R, Siuzdak G. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal Chem 2006; 78: 779-87. (Pubitemid 43228585)
14. Tibshirani R, Hastie T, Narashiman B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 2002; 99: 6567-72. (Pubitemid 34526173)
15. Anthony ML, Rose VS, Nicholson JK, Lindon JC. Classification of toxininduced changes in 1H NMR spectra of urine using an artificial neural network. J Pharm Biomed Anal 1995; 13: 205-11.
16. Beckonert O, Bollard ME, Ebbels T, Keun HC, Antti H, Holmes E, et al. NMR-based metabonomic toxicity classification: hierarchical cluster analysis and k-nearest. Anal Chim Acta 2003; 490: 3-15. (Pubitemid 37281288)
17. Fung ET, Wright GL Jr, Dalmasso EA. Proteomic strategies for biomarker identification: progress and challenges. Curr Opin Mol Ther 2000; 2: 643-50. (Pubitemid 32057560)
18. Skytt A, Thysell E, Stattin P, Stenman UH, Antti H, Wikström P. SELDITOF MS versus prostate specific antigen analysis of prospective plasma samples in a nested case control study of prostate cancer. Int J Cancer 2007; 121: 615-20. (Pubitemid 46986495)
19. Hundt S, Haug U, Brenner H. Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 2007; 16: 1935-53.
20. Wu CC, Chien KY, Tsang NM, Chang KP, Hao SP, Tsao CH, et al. Cancer cell-secreted proteomes as a basis for searching potential tumor markers: nasopharyngeal carcinoma as a model. Proteomics 2005; 5: 3173-82.
21. Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR, et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A 2003; 100: 3410-5. (Pubitemid 36356597)